Purple Biotech Ltd (NASDAQ:PPBT)

3.67
BATS BZX Real-Time Price
As of 3:36pm ET
 -0.17 / -4.43%
Today’s Change
3.60
Today|||52-Week Range
7.25
-5.66%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$72.4M

Company Description

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Tel Aviv, Israel.

Contact Information

Purple Biotech Ltd.
One Azrieli Center
Tel Aviv Tel Aviv 670110
P:(723) 933-3121
Investor Relations:

Employees

Shareholders

Mutual fund holders3.77%
Other institutional2.70%
Individual stakeholders--

Top Executives

Isaac IsraelChief Executive Officer & Director
Gil EfronPresident, Chief Financial Officer & Deputy CEO
Bertrand C. LiangChief Medical Officer
Fabien SebilleChief Business Officer
Michael SchicklerHead-Clinical Operations